|
G
|
Ctnnb1
|
catenin beta 1
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in increased expression of CTNNB1 protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in increased expression of CYP7A1 protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Cyp8b1
|
cytochrome P450 family 8 subfamily B member 1
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in increased expression of CYP8B1 protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in increased expression of IL1B protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Nr1h4
|
nuclear receptor subfamily 1, group H, member 4
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in decreased expression of NR1H4 protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389
|
|
G
|
Prkaa1
|
protein kinase AMP-activated catalytic subunit alpha 1
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in decreased phosphorylation of PRKAA1 protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450
|
|
G
|
Prkaa2
|
protein kinase AMP-activated catalytic subunit alpha 2
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in decreased phosphorylation of PRKAA2 protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:125,042,179...125,108,324
|
|
G
|
Scd
|
stearoyl-CoA desaturase
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in increased expression of SCD mRNA]
|
CTD |
PMID:35872049 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785
|
|
G
|
Sirt3
|
sirtuin 3
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in decreased expression of SIRT3 protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 1:205,371,703...205,394,145
Ensembl chr 1:205,371,710...205,394,076
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in increased expression of TGFB1 protein]
|
CTD |
PMID:35872049 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions
|
EXP
|
1,3,7,9-tetramethyluric acid inhibits the reaction [[Dietary Fats co-treated with Ethanol co-treated with Carbon Tetrachloride] results in increased expression of TNF protein]
|
CTD |
PMID:35872049 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
multiple interactions
|
ISO
|
[XDH protein alternative form results in increased metabolism of 1-methylxanthine] which results in increased chemical synthesis of 1-methyluric acid
|
CTD |
PMID:19215233 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
|
|
|
G
|
A1cf
|
APOBEC1 complementation factor
|
affects abundance
|
ISO
|
A1CF gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr 1:229,736,037...229,823,499
Ensembl chr 1:239,149,493...239,236,817
|
|
G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of ABCB11 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of ABCC2 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of ABCC3 mRNA; Uric Acid promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC3 mRNA]
|
CTD |
PMID:33749747 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
G
|
Abcc4
|
ATP binding cassette subfamily C member 4
|
affects export multiple interactions
|
ISO
|
ABCC4 protein affects the export of Uric Acid Uric Acid inhibits the reaction [ABCC4 protein affects the transport of Methotrexate]
|
CTD |
PMID:15454390 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375
|
|
G
|
Ace
|
angiotensin I converting enzyme
|
multiple interactions increases expression
|
ISO
|
APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of ACE mRNA]
|
CTD |
PMID:30710622 |
|
NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942
|
|
G
|
Acox1
|
acyl-CoA oxidase 1
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in decreased expression of ACOX1 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr10:101,905,083...101,930,136
Ensembl chr10:101,905,083...101,930,136
|
|
G
|
Acta2
|
actin alpha 2, smooth muscle
|
increases expression multiple interactions
|
EXP
|
Uric Acid results in increased expression of ACTA2 mRNA; Uric Acid results in increased expression of ACTA2 protein IL17A protein affects the reaction [Uric Acid results in increased expression of ACTA2 mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of ACTA2 protein]
|
CTD |
PMID:37815028 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
G
|
Agt
|
angiotensinogen
|
multiple interactions increases expression
|
ISO
|
resveratrol inhibits the reaction [Uric Acid results in increased expression of AGT mRNA]; resveratrol inhibits the reaction [Uric Acid results in increased expression of AGT protein] Uric Acid results in increased expression of AGT mRNA; Uric Acid results in increased expression of AGT protein APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of AGT mRNA]; APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of AGT protein modified form] Uric Acid results in increased expression of AGT mRNA; Uric Acid results in increased expression of AGT protein modified form
|
CTD |
PMID:25493383 PMID:30710622 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
G
|
Agtr1a
|
angiotensin II receptor, type 1a
|
multiple interactions increases expression
|
ISO
|
APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of AGTR1A mRNA]
|
CTD |
PMID:30710622 |
|
NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660
|
|
G
|
Agtr2
|
angiotensin II receptor, type 2
|
increases expression multiple interactions
|
ISO
|
Uric Acid results in increased expression of AGTR2 mRNA APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of AGTR2 mRNA]
|
CTD |
PMID:30710622 |
|
NCBI chr X:116,914,320...116,918,504
Ensembl chr X:116,913,656...116,918,745
|
|
G
|
Akr1b1
|
aldo-keto reductase family 1 member B1
|
multiple interactions increases expression
|
ISO
|
acetovanillone inhibits the reaction [Uric Acid results in increased expression of AKR1B1 mRNA]
|
CTD |
PMID:30651350 |
|
NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315
|
|
G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions increases phosphorylation
|
ISO
|
honokiol inhibits the reaction [Uric Acid results in increased phosphorylation of AKT1 protein]; nuciferine analog inhibits the reaction [Uric Acid results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:35687986 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
G
|
Alad
|
aminolevulinate dehydratase
|
multiple interactions
|
ISO
|
Uric Acid affects the reaction [ALAD polymorphism affects the susceptibility to Lead]
|
CTD |
PMID:16263504 |
|
NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041
|
|
G
|
Aldh16a1
|
aldehyde dehydrogenase 16 family, member A1
|
affects abundance
|
ISO
|
ALDH16A1 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:21983786 |
|
NCBI chr 1:104,763,200...104,776,270
Ensembl chr 1:104,763,055...104,776,270
|
|
G
|
Alpk1
|
alpha-kinase 1
|
increases expression multiple interactions increases response to substance
|
ISO
|
Uric Acid results in increased expression of ALPK1 mRNA ALPK1 protein promotes the reaction [Uric Acid results in increased secretion of TGFB1 protein] ALPK1 protein results in increased susceptibility to Uric Acid
|
CTD |
PMID:27542954 |
|
NCBI chr 2:218,801,425...218,924,013
Ensembl chr 2:218,780,189...218,921,646
|
|
G
|
Apln
|
apelin
|
multiple interactions
|
ISO
|
APLN protein modified form inhibits the reaction [Uric Acid results in decreased activity of CAT protein]; APLN protein modified form inhibits the reaction [Uric Acid results in decreased expression of APLNR mRNA]; APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of ACE mRNA]; APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of AGT mRNA]; APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of AGT protein modified form]; APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of AGTR1A mRNA]; APLN protein modified form inhibits the reaction [Uric Acid results in increased expression of AGTR2 mRNA]
|
CTD |
PMID:30710622 |
|
NCBI chr X:132,058,739...132,091,518
Ensembl chr X:132,081,759...132,091,246
|
|
G
|
Aplnr
|
apelin receptor
|
multiple interactions decreases expression
|
ISO
|
APLN protein modified form inhibits the reaction [Uric Acid results in decreased expression of APLNR mRNA]
|
CTD |
PMID:30710622 |
|
NCBI chr 3:90,624,055...90,627,700
Ensembl chr 3:90,624,012...90,627,908
|
|
G
|
App
|
amyloid beta precursor protein
|
multiple interactions
|
ISO
|
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Uric Acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Uric Acid]
|
CTD |
PMID:39172838 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
G
|
Aqp1
|
aquaporin 1
|
multiple interactions
|
ISO
|
AQP1 mRNA affects the reaction [Uric Acid results in increased secretion of IL1B protein]
|
CTD |
PMID:21051542 |
|
NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504
|
|
G
|
Aqp9
|
aquaporin 9
|
multiple interactions
|
ISO
|
AQP9 mRNA affects the reaction [Uric Acid results in increased secretion of IL1B protein]
|
CTD |
PMID:21051542 |
|
NCBI chr 8:80,678,027...80,718,273
Ensembl chr 8:80,678,030...80,717,240
|
|
G
|
Arg1
|
arginase 1
|
increases expression multiple interactions
|
EXP
|
Uric Acid results in increased expression of ARG1 protein Colchicine promotes the reaction [Uric Acid results in increased expression of ARG1 protein]; simiaowan promotes the reaction [Uric Acid results in increased expression of ARG1 protein]
|
CTD |
PMID:33894285 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
G
|
Atf4
|
activating transcription factor 4
|
multiple interactions
|
ISO
|
Uric Acid inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of ATF4 mRNA]
|
CTD |
PMID:21703327 |
|
NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739
|
|
G
|
Atr
|
ATR serine/threonine kinase
|
multiple interactions increases phosphorylation
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in increased phosphorylation of ATR protein]
|
CTD |
PMID:23619996 |
|
NCBI chr 8:105,306,299...105,403,742
Ensembl chr 8:105,306,305...105,403,718
|
|
G
|
Atxn2
|
ataxin 2
|
affects abundance
|
ISO
|
ATXN2 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr12:40,413,657...40,509,895
Ensembl chr12:40,414,904...40,510,473
|
|
G
|
B3gnt4
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4
|
affects abundance
|
ISO
|
B3GNT4 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr12:38,729,653...38,734,911
Ensembl chr12:38,728,889...38,734,744
|
|
G
|
Baz1b
|
bromodomain adjacent to zinc finger domain, 1B
|
affects abundance
|
ISO
|
BAZ1B gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr12:27,068,541...27,126,511
Ensembl chr12:27,068,541...27,126,511
|
|
G
|
Brca1
|
BRCA1, DNA repair associated
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of BRCA1 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763
|
|
G
|
Casp1
|
caspase 1
|
multiple interactions increases cleavage increases expression increases phosphorylation
|
ISO EXP
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Uric Acid] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]; [Lipopolysaccharides co-treated with Uric Acid] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of and results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of CASP1 protein; [Uric Acid affects the susceptibility to [Air Pollutants results in increased abundance of Particulate Matter]] which results in increased activity of CASP1 protein; CASP1 gene mutant form inhibits the reaction [Uric Acid results in increased phosphorylation of H2AX protein]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of CASP1 protein]; leojaponin inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of and results in increased activity of CASP1 protein]; leojaponin inhibits the reaction [Uric Acid results in increased cleavage of and results in increased activity of CASP1 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Uric Acid] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [Uric Acid results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [Uric Acid results in increased cleavage of CASP1 protein]; Silicon Dioxide analog inhibits the reaction [Uric Acid results in increased cleavage of CASP1 protein]; Uric Acid results in increased cleavage of and results in increased activity of CASP1 protein [Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein; Apigenin inhibits the reaction [Uric Acid results in increased expression of and results in increased cleavage of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [Uric Acid results in increased cleavage of CASP1 protein]; nuciferine inhibits the reaction [Uric Acid results in increased expression of CASP1 protein] Uric Acid results in increased expression of CASP1 protein; Uric Acid results in increased expression of CASP1 protein modified form Uric Acid results in increased phosphorylation of CASP1 protein Colchicine inhibits the reaction [Uric Acid results in increased expression of and results in increased cleavage of CASP1 protein]; evodiamine inhibits the reaction [Uric Acid results in increased expression of and results in increased cleavage of CASP1 protein]; Uric Acid results in increased expression of and results in increased cleavage of CASP1 protein
|
CTD |
PMID:18403674 PMID:18604214 PMID:23430110 PMID:23619996 PMID:25499818 PMID:29960001 PMID:30842373 PMID:34118343 PMID:36577999 PMID:36796188 PMID:37062408 PMID:37555854 More...
|
|
NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275
|
|
G
|
Cat
|
catalase
|
increases expression decreases activity multiple interactions
|
ISO
|
Uric Acid results in increased expression of CAT protein Uric Acid results in decreased activity of CAT protein APLN protein modified form inhibits the reaction [Uric Acid results in decreased activity of CAT protein]
|
CTD |
PMID:23619996 PMID:30710622 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526
|
|
G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions increases secretion increases expression
|
ISO EXP
|
[Fructose co-treated with Uric Acid] results in increased secretion of CCL2 protein; Allopurinol inhibits the reaction [[Fructose co-treated with Uric Acid] results in increased secretion of CCL2 protein] Uric Acid results in increased secretion of CCL2 protein Uric Acid results in increased expression of CCL2 protein Probenecid inhibits the reaction [Uric Acid results in increased expression of CCL2 protein]
|
CTD |
PMID:16113518 PMID:19158351 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
G
|
Ccnb1
|
cyclin B1
|
decreases expression multiple interactions
|
ISO
|
Uric Acid results in decreased expression of CCNB1 mRNA NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of CCNB1 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
G
|
Ccnd1
|
cyclin D1
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of CCND1 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
G
|
Col1a1
|
collagen type I alpha 1 chain
|
multiple interactions increases expression
|
EXP
|
IL17A protein affects the reaction [Uric Acid results in increased expression of COL1A1 mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of COL1A1 protein] Uric Acid results in increased expression of COL1A1 mRNA; Uric Acid results in increased expression of COL1A1 protein
|
CTD |
PMID:37815028 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
G
|
Col2a1
|
collagen type II alpha 1 chain
|
multiple interactions
|
EXP
|
[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; Dexamethasone inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]
|
CTD |
PMID:24709313 |
|
NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627
|
|
G
|
Cp
|
ceruloplasmin
|
affects activity
|
ISO
|
Uric Acid affects the activity of CP protein
|
CTD |
PMID:10949969 |
|
NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087
|
|
G
|
Ctsb
|
cathepsin B
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of CTSB protein
|
CTD |
PMID:18604214 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478
|
|
G
|
Cyba
|
cytochrome b-245 alpha chain
|
multiple interactions
|
ISO
|
CYBA protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]
|
CTD |
PMID:18403674 |
|
NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214
|
|
G
|
Cyp7a1
|
cytochrome P450 family 7 subfamily A member 1
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in decreased expression of CYP7A1 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 5:24,174,505...24,184,202
Ensembl chr 5:24,174,505...24,184,202
|
|
G
|
Cyp8b1
|
cytochrome P450 family 8 subfamily B member 1
|
multiple interactions decreases expression
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in decreased expression of CYP8B1 mRNA Uric Acid results in decreased expression of CYP8B1 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689
|
|
G
|
Ddit3
|
DNA-damage inducible transcript 3
|
multiple interactions
|
ISO
|
Uric Acid inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of DDIT3 mRNA]
|
CTD |
PMID:21703327 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
G
|
Edn1
|
endothelin 1
|
multiple interactions increases expression
|
ISO
|
resveratrol inhibits the reaction [Uric Acid results in increased expression of EDN1 mRNA]; resveratrol inhibits the reaction [Uric Acid results in increased expression of EDN1 protein] Uric Acid results in increased expression of EDN1 mRNA; Uric Acid results in increased expression of EDN1 protein
|
CTD |
PMID:25493383 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
G
|
Fn1
|
fibronectin 1
|
increases expression multiple interactions
|
ISO
|
Uric Acid results in increased expression of FN1 mRNA salinomycin inhibits the reaction [Uric Acid results in increased expression of FN1 mRNA]
|
CTD |
PMID:39222901 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137
|
|
G
|
Gnai2
|
G protein subunit alpha i2
|
multiple interactions
|
EXP
|
Uric Acid inhibits the reaction [Glucose results in decreased expression of GNAI2 protein]; Uric Acid inhibits the reaction [Peroxynitrous Acid results in decreased expression of GNAI2 protein]; Uric Acid inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI2 protein]
|
CTD |
PMID:16962941 PMID:18055527 PMID:18441196 |
|
NCBI chr 8:117,167,045...117,187,652
Ensembl chr 8:117,167,045...117,187,622
|
|
G
|
Gnai3
|
G protein subunit alpha i3
|
multiple interactions
|
EXP
|
Uric Acid inhibits the reaction [Glucose results in decreased expression of GNAI3 protein]; Uric Acid inhibits the reaction [Peroxynitrous Acid results in decreased expression of GNAI3 protein]; Uric Acid inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of GNAI3 protein]
|
CTD |
PMID:16962941 PMID:18055527 PMID:18441196 |
|
NCBI chr 2:198,430,920...198,468,874
|
|
G
|
Gpx2
|
glutathione peroxidase 2
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of GPX2 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862
|
|
G
|
Gsdmd
|
gasdermin D
|
multiple interactions
|
ISO
|
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Uric Acid] results in increased cleavage of GSDMD protein; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Uric Acid] results in increased cleavage of GSDMD protein]
|
CTD |
PMID:36577999 |
|
NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722
|
|
G
|
Gsta2
|
glutathione S-transferase alpha 2
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of GSTA2 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092
|
|
G
|
Gstm5
|
glutathione S-transferase, mu 5
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of GSTM3 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 2:198,219,769...198,222,732
Ensembl chr 2:198,219,647...198,222,731
|
|
G
|
Gstt1
|
glutathione S-transferase theta 1
|
affects abundance
|
ISO
|
GSTT1 protein polymorphism affects the abundance of Uric Acid
|
CTD |
PMID:23747713 |
|
NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019
|
|
G
|
H2ax
|
H2A.X variant histone
|
increases phosphorylation multiple interactions
|
ISO
|
Uric Acid results in increased phosphorylation of H2AX protein CASP1 gene mutant form inhibits the reaction [Uric Acid results in increased phosphorylation of H2AX protein]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in increased phosphorylation of H2AX protein]
|
CTD |
PMID:23619996 |
|
NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079
|
|
G
|
Hadha
|
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha
|
multiple interactions decreases expression
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in decreased expression of HADHA mRNA Uric Acid results in decreased expression of HADHA mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 6:31,907,801...31,947,434
Ensembl chr 6:31,907,291...31,947,698
|
|
G
|
Havcr1
|
hepatitis A virus cellular receptor 1
|
increases expression multiple interactions
|
EXP
|
Uric Acid results in increased expression of HAVCR1 protein IL17A protein affects the reaction [Uric Acid results in increased expression of HAVCR1 protein]
|
CTD |
PMID:37815028 |
|
NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268
|
|
G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of HIF1A mRNA; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of HIF1A mRNA]
|
CTD |
PMID:36796188 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
G
|
Hlf
|
HLF transcription factor, PAR bZIP family member
|
affects abundance
|
ISO
|
HLF gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr10:75,651,320...75,708,979
Ensembl chr10:75,654,534...75,708,619
|
|
G
|
Hnf4g
|
hepatocyte nuclear factor 4, gamma
|
affects abundance
|
ISO
|
HNF4G gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr 2:99,792,942...99,943,811
Ensembl chr 2:99,792,942...99,943,811
|
|
G
|
Igf1r
|
insulin-like growth factor 1 receptor
|
affects abundance
|
ISO
|
IGF1R gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664
|
|
G
|
Il10
|
interleukin 10
|
multiple interactions
|
EXP
|
[Colchicine co-treated with Uric Acid] results in increased expression of IL10 protein; [simiaowan co-treated with Uric Acid] results in increased expression of IL10 protein
|
CTD |
PMID:33894285 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
G
|
Il17a
|
interleukin 17A
|
multiple interactions increases expression
|
EXP
|
IL17A protein affects the reaction [Uric Acid results in increased expression of ACTA2 mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of ACTA2 protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of and results in increased phosphorylation of RELA protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of COL1A1 mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of COL1A1 protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of HAVCR1 protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of IL1B mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of IL1B protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of IL6 mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of IL6 protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of TNF mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of TNF protein] Uric Acid results in increased expression of IL17A protein
|
CTD |
PMID:37815028 |
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331
|
|
G
|
Il18
|
interleukin 18
|
multiple interactions increases expression
|
EXP
|
Colchicine inhibits the reaction [Uric Acid results in increased expression of IL18 protein]; evodiamine inhibits the reaction [Uric Acid results in increased expression of IL18 protein]
|
CTD |
PMID:37555854 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
G
|
Il1b
|
interleukin 1 beta
|
multiple interactions increases expression increases secretion
|
EXP ISO
|
Colchicine inhibits the reaction [Uric Acid results in increased expression of IL1B protein]; Drugs, Chinese Herbal inhibits the reaction [Uric Acid results in increased expression of IL1B mRNA]; Drugs, Chinese Herbal inhibits the reaction [Uric Acid results in increased expression of IL1B protein]; evodiamine inhibits the reaction [Uric Acid results in increased expression of IL1B protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of IL1B mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of IL1B protein]; simiaowan inhibits the reaction [Uric Acid results in increased expression of IL1B protein] Uric Acid results in increased expression of IL1B mRNA; Uric Acid results in increased expression of IL1B protein 2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [Uric Acid promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; [Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased expression of IL1B protein; [Uric Acid co-treated with TGFB1 protein] promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Acetylcysteine inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Ammonium Chloride inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Apigenin inhibits the reaction [Uric Acid results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein]; AQP1 mRNA affects the reaction [Uric Acid results in increased secretion of IL1B protein]; AQP9 mRNA affects the reaction [Uric Acid results in increased secretion of IL1B protein]; CASP1 protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; Chloroquine inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of and results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; diphenyleneiodonium inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; flavone analog inhibits the reaction [Uric Acid results in increased cleavage of and results in increased secretion of IL1B protein]; latrunculin A inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Mercuric Chloride inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine inhibits the reaction [Uric Acid results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; nuciferine inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Phloretin inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; TGFBR2 protein affects the reaction [Uric Acid promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [Uric Acid results in increased cleavage of and results in increased secretion of IL1B protein]; Uric Acid promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Uric Acid results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Uric Acid] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]; [Lipopolysaccharides co-treated with Uric Acid] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of and results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of IL1B protein; acetovanillone inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of IL1B protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Chloroquine inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of IL1B protein]; CYBA protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of and results in increased secretion of IL1B protein]; diallyl disulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of IL1B protein]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of and results in increased secretion of IL1B protein]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of IL1B mRNA]; leojaponin inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of IL1B protein]; leojaponin inhibits the reaction [[Nigericin co-treated with Uric Acid] results in increased secretion of IL1B protein]; leojaponin inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Uric Acid] results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of and results in increased cleavage of IL1B protein]; NLRP3 protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of and results in increased cleavage of IL1B protein]; PYCARD protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; salinomycin inhibits the reaction [Uric Acid results in increased expression of IL1B mRNA]; salinomycin inhibits the reaction [Uric Acid results in increased expression of IL1B protein]; TXN protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; UOX protein inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of IL1B protein]; Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B mRNA]
|
CTD |
PMID:18403674 PMID:18604214 PMID:19655406 PMID:21051542 PMID:23430110 PMID:24158569 PMID:25499818 PMID:26296894 PMID:27542954 PMID:29960001 PMID:33749747 PMID:33894285 PMID:34118343 PMID:36002070 PMID:36577999 PMID:36796188 PMID:36850003 PMID:37555854 PMID:37815028 PMID:39222901 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
G
|
Il1rn
|
interleukin 1 receptor antagonist
|
multiple interactions
|
ISO
|
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [Uric Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1RN protein]]; TGFBR2 protein affects the reaction [Uric Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1RN protein]]; Uric Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1RN protein]
|
CTD |
PMID:36850003 |
|
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732
|
|
G
|
Il6
|
interleukin 6
|
multiple interactions increases expression
|
ISO EXP
|
salinomycin inhibits the reaction [Uric Acid results in increased expression of IL6 mRNA]; Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL6 mRNA]; Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL6 protein] [Uric Acid co-treated with TGFB1 protein] promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Uric Acid results in increased expression of IL6 mRNA; Uric Acid results in increased expression of IL6 protein IL17A protein affects the reaction [Uric Acid results in increased expression of IL6 mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of IL6 protein]
|
CTD |
PMID:33749747 PMID:36850003 PMID:37815028 PMID:39222901 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
G
|
Inhbb
|
inhibin subunit beta B
|
affects abundance
|
ISO
|
INHBB gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr13:33,083,671...33,089,373
Ensembl chr13:33,083,671...33,089,609
|
|
G
|
Itpr1
|
inositol 1,4,5-trisphosphate receptor, type 1
|
multiple interactions
|
ISO
|
Uric Acid inhibits the reaction [Ethanol results in increased expression of and affects the localization of ITPR1 protein]
|
CTD |
PMID:17241155 |
|
NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504
|
|
G
|
Jak2
|
Janus kinase 2
|
increases phosphorylation multiple interactions
|
EXP
|
Uric Acid results in increased phosphorylation of JAK2 protein Colchicine promotes the reaction [Uric Acid results in increased phosphorylation of JAK2 protein]; simiaowan promotes the reaction [Uric Acid results in increased phosphorylation of JAK2 protein]
|
CTD |
PMID:33894285 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762
|
|
G
|
Keap1
|
Kelch-like ECH-associated protein 1
|
multiple interactions increases expression
|
ISO
|
salinomycin inhibits the reaction [Uric Acid results in increased expression of KEAP1 mRNA]
|
CTD |
PMID:39222901 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042
|
|
G
|
Khk
|
ketohexokinase
|
increases expression
|
EXP ISO
|
Uric Acid results in increased expression of KHK protein
|
CTD |
PMID:30651350 |
|
NCBI chr 6:31,165,246...31,175,779
Ensembl chr 6:31,165,248...31,175,481
|
|
G
|
Lepr
|
leptin receptor
|
multiple interactions increases abundance
|
ISO
|
swietenine inhibits the reaction [LEPR gene mutant form results in increased abundance of Uric Acid]
|
CTD |
PMID:36066211 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215
|
|
G
|
Maf
|
MAF bZIP transcription factor
|
affects abundance
|
ISO
|
MAF gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378
|
|
G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions
|
EXP
|
Uric Acid inhibits the reaction [Ammonium Chloride results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:11923223 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions
|
EXP
|
Uric Acid inhibits the reaction [Ammonium Chloride results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:11923223 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
G
|
Mmp9
|
matrix metallopeptidase 9
|
increases expression
|
ISO
|
Uric Acid results in increased expression of MMP9 mRNA
|
CTD |
PMID:36850003 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO
|
Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of MPO protein]
|
CTD |
PMID:33749747 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
increases expression multiple interactions
|
ISO
|
Uric Acid results in increased expression of MYD88 protein nuciferine inhibits the reaction [Uric Acid results in increased expression of MYD88 protein]
|
CTD |
PMID:25499818 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
G
|
Nfat5
|
nuclear factor of activated T-cells 5
|
affects abundance affects localization
|
ISO
|
NFAT5 gene SNP affects the abundance of Uric Acid Uric Acid affects the localization of NFAT5 protein
|
CTD |
PMID:23263486 PMID:30651350 |
|
NCBI chr19:52,108,982...52,196,418
Ensembl chr19:52,109,483...52,196,418
|
|
G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
multiple interactions
|
ISO
|
salinomycin inhibits the reaction [Uric Acid results in decreased expression of and results in decreased phosphorylation of NFE2L2 protein]; Uric Acid results in decreased expression of and results in decreased phosphorylation of NFE2L2 protein
|
CTD |
PMID:39222901 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions decreases expression
|
EXP
|
Colchicine inhibits the reaction [Uric Acid results in decreased expression of NFKBIA protein]; simiaowan inhibits the reaction [Uric Acid results in decreased expression of NFKBIA protein]
|
CTD |
PMID:33894285 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
G
|
Nlrp3
|
NLR family, pyrin domain containing 3
|
multiple interactions increases expression decreases response to substance
|
ISO EXP
|
[Lipopolysaccharides co-treated with Uric Acid] affects the localization of NLRP3 protein; [Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] affects the localization of NLRP3 protein]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of BRCA1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of CCNB1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of CCND1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of OGG1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of POLB mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of PRIM1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RAD51 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RFC3 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RFC4 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of TTK mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of TYMS mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of XRCC1 mRNA]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in increased phosphorylation of ATR protein]; NLRP3 gene mutant form inhibits the reaction [Uric Acid results in increased phosphorylation of H2AX protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of and results in increased cleavage of IL1B protein]; NLRP3 protein affects the reaction [Uric Acid results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [Uric Acid results in increased secretion of IL1B protein] Uric Acid results in increased expression of NLRP3 protein Colchicine inhibits the reaction [Uric Acid results in increased expression of NLRP3 protein]; evodiamine inhibits the reaction [Uric Acid results in increased expression of NLRP3 protein] [Uric Acid co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; NLRP3 protein affects the reaction [Uric Acid results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; nuciferine inhibits the reaction [Uric Acid results in increased expression of NLRP3 protein] NLRP3 gene mutant form results in decreased susceptibility to Uric Acid
|
CTD |
PMID:18403674 PMID:18604214 PMID:23619996 PMID:25499818 PMID:36796188 PMID:37555854 More...
|
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394
|
|
G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions increases expression
|
ISO EXP
|
Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NOS2 mRNA] Uric Acid results in increased expression of NOS2 protein Colchicine inhibits the reaction [Uric Acid results in increased expression of NOS2 protein]; simiaowan inhibits the reaction [Uric Acid results in increased expression of NOS2 protein]
|
CTD |
PMID:33749747 PMID:33894285 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
G
|
Nos3
|
nitric oxide synthase 3
|
increases abundance
|
ISO
|
NOS3 gene mutant form results in increased abundance of Uric Acid
|
CTD |
PMID:12947532 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
G
|
Nox3
|
NADPH oxidase 3
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of NOX3 mRNA; [Lipopolysaccharides co-treated with Uric Acid] results in increased expression of NOX3 protein; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of NOX3 mRNA]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of NOX3 protein]
|
CTD |
PMID:36796188 |
|
NCBI chr 1:46,643,277...46,708,109
Ensembl chr 1:46,642,564...46,708,109
|
|
G
|
Nox4
|
NADPH oxidase 4
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of NOX4 mRNA; [Lipopolysaccharides co-treated with Uric Acid] results in increased expression of NOX4 protein; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of NOX4 mRNA]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of NOX4 protein]
|
CTD |
PMID:36796188 |
|
NCBI chr 1:150,313,736...150,491,480
Ensembl chr 1:150,313,728...150,491,483
|
|
G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of NQO1 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
G
|
Nr0b2
|
nuclear receptor subfamily 0, group B, member 2
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of NR0B2 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:151,063,160...151,066,475
|
|
G
|
Ogg1
|
8-oxoguanine DNA glycosylase
|
decreases expression multiple interactions
|
ISO
|
Uric Acid results in decreased expression of OGG1 mRNA NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of OGG1 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr 4:148,030,237...148,037,599
Ensembl chr 4:148,030,349...148,037,604
|
|
G
|
Parp1
|
poly (ADP-ribose) polymerase 1
|
multiple interactions
|
ISO
|
Uric Acid inhibits the reaction [sodium arsenite inhibits the reaction [PARP1 protein binds to Zinc]]; Uric Acid inhibits the reaction [sodium arsenite results in decreased activity of and results in increased nitrosation of PARP1 protein]
|
CTD |
PMID:31152818 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567
|
|
G
|
Pawr
|
pro-apoptotic WT1 regulator
|
multiple interactions
|
EXP
|
Uric Acid inhibits the reaction [Nerve Growth Factors deficiency results in increased expression of PAWR mRNA]; Uric Acid inhibits the reaction [Nerve Growth Factors deficiency results in increased expression of PAWR protein]
|
CTD |
PMID:10428045 |
|
NCBI chr 7:45,531,480...45,611,492
Ensembl chr 7:45,531,637...45,611,492
|
|
G
|
Pml
|
PML nuclear body scaffold
|
multiple interactions
|
ISO
|
PML protein promotes the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of IL1B protein]; Uric Acid promotes the reaction [Lipopolysaccharides results in increased expression of PML protein]
|
CTD |
PMID:23430110 |
|
NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083
|
|
G
|
Polb
|
DNA polymerase beta
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of POLB mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr16:76,081,903...76,105,174
Ensembl chr16:76,081,864...76,108,180
|
|
G
|
Pon1
|
paraoxonase 1
|
affects abundance
|
ISO
|
PON1 protein polymorphism affects the abundance of Uric Acid
|
CTD |
PMID:23747713 |
|
NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924
|
|
G
|
Ppara
|
peroxisome proliferator activated receptor alpha
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in decreased expression of PPARA protein
|
CTD |
PMID:33749747 |
|
NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714
|
|
G
|
Prdx1
|
peroxiredoxin 1
|
increases expression
|
ISO
|
Uric Acid results in increased expression of PRDX1 protein
|
CTD |
PMID:23619996 |
|
NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:135,383,906...135,399,504
|
|
G
|
Prim1
|
DNA primase subunit 1
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of PRIM1 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr 7:1,031,436...1,047,134
|
|
G
|
Prkag2
|
protein kinase AMP-activated non-catalytic subunit gamma 2
|
affects abundance
|
ISO
|
PRKAG2 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr 4:10,744,695...10,985,939
Ensembl chr 4:10,744,588...10,985,939
|
|
G
|
Prkg2
|
protein kinase cGMP-dependent 2
|
decreases expression
|
ISO
|
Uric Acid results in decreased expression of PRKG2 mRNA
|
CTD |
PMID:27542954 |
|
NCBI chr14:10,864,020...10,972,617
Ensembl chr14:10,864,186...10,972,614
|
|
G
|
Psen1
|
presenilin 1
|
multiple interactions
|
ISO
|
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Uric Acid; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Uric Acid]
|
CTD |
PMID:39172838 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189
|
|
G
|
Ptk2b
|
protein tyrosine kinase 2 beta
|
multiple interactions increases phosphorylation
|
ISO
|
Apigenin inhibits the reaction [Uric Acid results in increased phosphorylation of PTK2B protein]
|
CTD |
PMID:29960001 |
|
NCBI chr15:44,536,275...44,656,754
Ensembl chr15:44,531,249...44,656,806
|
|
G
|
Pycard
|
PYD and CARD domain containing
|
multiple interactions increases expression
|
ISO EXP
|
[Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]; [Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to PYCARD protein]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to CASP1 protein binds to IL1B protein binds to NLRP3 protein]]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] promotes the reaction [PYCARD protein binds to PYCARD protein]]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of and results in increased cleavage of IL1B protein]; PYCARD protein affects the reaction [Uric Acid results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [Uric Acid results in increased secretion of IL1B protein] Uric Acid results in increased expression of PYCARD protein Colchicine inhibits the reaction [Uric Acid results in increased expression of PYCARD protein]; evodiamine inhibits the reaction [Uric Acid results in increased expression of PYCARD protein] Apigenin inhibits the reaction [Uric Acid promotes the reaction [PYCARD protein binds to PYCARD protein]]; kaempferol inhibits the reaction [Uric Acid promotes the reaction [PYCARD protein binds to PYCARD protein]]; nuciferine inhibits the reaction [Uric Acid results in increased expression of PYCARD protein]; PYCARD protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]; Uric Acid promotes the reaction [PYCARD protein binds to PYCARD protein]
|
CTD |
PMID:18403674 PMID:18604214 PMID:25499818 PMID:29960001 PMID:36796188 PMID:37555854 More...
|
|
NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419
|
|
G
|
Rad51
|
RAD51 recombinase
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RAD51 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
multiple interactions increases phosphorylation
|
EXP ISO
|
Colchicine inhibits the reaction [Uric Acid results in increased phosphorylation of RELA protein]; Drugs, Chinese Herbal inhibits the reaction [Uric Acid results in increased localization of and results in increased activity of RELA protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of and results in increased phosphorylation of RELA protein]; simiaowan inhibits the reaction [Uric Acid results in increased phosphorylation of RELA protein]; Uric Acid results in increased expression of and results in increased phosphorylation of RELA protein; Uric Acid results in increased localization of and results in increased activity of RELA protein nuciferine inhibits the reaction [Uric Acid results in increased phosphorylation of RELA protein] Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of RELA protein]
|
CTD |
PMID:19655406 PMID:25499818 PMID:33749747 PMID:33894285 PMID:37815028 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
G
|
Rfc3
|
replication factor C subunit 3
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RFC3 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340
|
|
G
|
Rfc4
|
replication factor C subunit 4
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of RFC4 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr11:91,254,273...91,268,727
Ensembl chr11:91,254,243...91,268,730
|
|
G
|
Sfmbt1
|
Scm-like with four mbt domains 1
|
affects abundance
|
ISO
|
SFMBT1 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr16:5,889,046...6,009,860
Ensembl chr16:5,897,187...6,011,934
|
|
G
|
Slc10a1
|
solute carrier family 10 member 1
|
multiple interactions
|
ISO
|
Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]
|
CTD |
PMID:33749747 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:106,344,319...106,357,944
|
|
G
|
Slc12a2
|
solute carrier family 12 member 2
|
multiple interactions
|
EXP
|
Uric Acid inhibits the reaction [Manganese results in increased expression of SLC12A2 protein]; Uric Acid inhibits the reaction [Manganese results in increased phosphorylation of and results in increased activity of SLC12A2 protein]
|
CTD |
PMID:25817889 |
|
NCBI chr18:53,546,263...53,614,478
Ensembl chr18:53,546,333...53,614,470
|
|
G
|
Slc17a3
|
solute carrier family 17 member 3
|
affects transport
|
ISO
|
SLC17A3 gene SNP affects the transport of Uric Acid
|
CTD |
PMID:21282933 |
|
NCBI chr17:41,698,679...41,729,057
Ensembl chr17:41,698,680...41,723,329
|
|
G
|
Slc22a12
|
solute carrier family 22 member 12
|
increases import increases expression increases uptake affects transport multiple interactions increases export
|
ISO EXP
|
SLC22A12 protein results in increased import of Uric Acid Uric Acid results in increased expression of SLC22A12 protein SLC22A12 protein results in increased uptake of Uric Acid SLC22A12 protein affects the transport of Uric Acid Benzbromarone inhibits the reaction [SLC22A12 protein affects the transport of Uric Acid]; Chlorides affects the reaction [SLC22A12 protein affects the transport of Uric Acid]; Lactic Acid promotes the reaction [SLC22A12 protein affects the transport of Uric Acid]; pyrazinoic acid promotes the reaction [SLC22A12 protein affects the transport of Uric Acid] SLC22A12 protein results in increased export of Uric Acid Benzbromarone inhibits the reaction [SLC22A12 protein affects the transport of Uric Acid]; gluconic acid promotes the reaction [SLC22A12 protein affects the transport of Uric Acid]; Lactic Acid affects the reaction [SLC22A12 protein affects the transport of Uric Acid]; Probenecid inhibits the reaction [SLC22A12 protein affects the transport of Uric Acid]; pyrazinoic acid promotes the reaction [SLC22A12 protein affects the transport of Uric Acid] 6-hydroxybenzbromarone inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; [Chlorine co-treated with perfluoro-n-heptanoic acid] inhibits the reaction [SLC22A12 protein results in increased import of Uric Acid]; [Chlorine co-treated with perfluoro-n-nonanoic acid] inhibits the reaction [SLC22A12 protein results in increased import of Uric Acid]; [Chlorine co-treated with perfluorodecanoic acid] inhibits the reaction [SLC22A12 protein results in increased import of Uric Acid]; [Chlorine co-treated with perfluorooctanoic acid] inhibits the reaction [SLC22A12 protein results in increased import of Uric Acid]; [Losartan results in decreased activity of SLC22A12 protein] which results in decreased abundance of Uric Acid; benzarone inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; Benzbromarone inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; Chlorine inhibits the reaction [SLC22A12 protein results in increased import of Uric Acid]; E 3040 inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; Enalapril inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; honokiol inhibits the reaction [Uric Acid results in increased expression of SLC22A12 protein]; Indomethacin inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; nuciferine analog inhibits the reaction [Uric Acid results in increased expression of SLC22A12 protein]; Phenylbutazone inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; Probenecid inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; Salicylates inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; Sulfinpyrazone inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid]; Uric Acid inhibits the reaction [SLC22A12 protein results in increased uptake of Oxypurinol]
|
CTD |
PMID:14694169 PMID:14747372 PMID:15284287 PMID:16135657 PMID:18670416 PMID:20639259 PMID:21074513 PMID:21272127 PMID:21449597 PMID:33007874 PMID:35687986 More...
|
|
NCBI chr 1:213,274,266...213,282,793
Ensembl chr 1:213,274,275...213,281,380
|
|
G
|
Slc22a20
|
solute carrier family 22 member 20
|
multiple interactions
|
ISO
|
Uric Acid inhibits the reaction [SLC22A20 protein results in increased uptake of estrone sulfate]
|
CTD |
PMID:16478971 |
|
NCBI chr 1:212,686,691...212,703,163
Ensembl chr 1:212,686,691...212,703,163
|
|
G
|
Slc22a6
|
solute carrier family 22 member 6
|
multiple interactions affects secretion increases uptake
|
ISO EXP
|
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]; Benzbromarone inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]; gluconic acid inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]; Glutarates promotes the reaction [SLC22A6 protein results in increased uptake of Uric Acid]; Ketoglutaric Acids inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]; p-Aminohippuric Acid inhibits the reaction [SLC22A6 protein results in increased uptake of Uric Acid]; Probenecid inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]; pyrazinoic acid inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]; Salicylates inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid] SLC22A6 protein affects the secretion of Uric Acid [Oxonic Acid co-treated with Uric Acid] results in decreased expression of SLC22A6 protein
|
CTD |
PMID:12472777 PMID:19605544 |
|
NCBI chr 1:214,951,493...214,960,317
Ensembl chr 1:214,951,867...214,960,311
|
|
G
|
Slc22a8
|
solute carrier family 22 member 8
|
affects transport multiple interactions
|
ISO EXP
|
SLC22A8 protein affects the transport of Uric Acid [Oxonic Acid co-treated with Uric Acid] results in decreased expression of SLC22A8 protein
|
CTD |
PMID:11306713 PMID:19605544 |
|
NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588
|
|
G
|
Slc2a6
|
solute carrier family 2 member 6
|
increases expression multiple interactions
|
ISO
|
Uric Acid results in increased expression of SLC2A6 protein honokiol inhibits the reaction [Uric Acid results in increased expression of SLC2A6 protein]; nuciferine analog inhibits the reaction [Uric Acid results in increased expression of SLC2A6 protein]
|
CTD |
PMID:35687986 |
|
NCBI chr 3:30,746,472...30,753,287
Ensembl chr 3:30,745,995...30,753,287
|
|
G
|
Slc2a9
|
solute carrier family 2 member 9
|
multiple interactions decreases secretion affects transport increases transport affects abundance
|
ISO
|
Benzbromarone inhibits the reaction [SLC2A9 protein alternative form results in increased transport of Uric Acid]; Fructose promotes the reaction [SLC2A9 protein alternative form results in increased transport of Uric Acid]; Glucose promotes the reaction [SLC2A9 protein alternative form results in increased transport of Uric Acid] SLC2A9 protein results in decreased secretion of Uric Acid SLC2A9 protein alternative form affects the transport of Uric Acid Benzbromarone inhibits the reaction [SLC2A9 protein results in increased uptake of Uric Acid]; Losartan inhibits the reaction [SLC2A9 protein results in increased uptake of Uric Acid]; Phloretin inhibits the reaction [SLC2A9 protein results in increased uptake of Uric Acid] SLC2A9 protein affects the transport of Uric Acid SLC2A9 gene polymorphism affects the abundance of Uric Acid; SLC2A9 intron SNP affects the abundance of Uric Acid
|
CTD |
PMID:18327256 PMID:18327257 PMID:18842065 PMID:19587147 PMID:22132990 |
|
NCBI chr14:76,540,649...76,674,277
Ensembl chr14:76,540,571...76,674,277
|
|
G
|
Slc51b
|
SLC51 subunit beta
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of SLC51B mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109
|
|
G
|
Slco1b2
|
solute carrier organic anion transporter family member 1B2
|
multiple interactions
|
ISO
|
[1-Naphthylisothiocyanate co-treated with Uric Acid] results in decreased expression of SLCO1B2 mRNA
|
CTD |
PMID:33749747 |
|
NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083
|
|
G
|
Smad2
|
SMAD family member 2
|
increases phosphorylation
|
ISO
|
Uric Acid results in increased phosphorylation of SMAD2 protein
|
CTD |
PMID:36850003 |
|
NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388
|
|
G
|
Smad7
|
SMAD family member 7
|
decreases expression
|
ISO
|
Uric Acid results in decreased expression of SMAD7 mRNA
|
CTD |
PMID:36850003 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849
|
|
G
|
Sod1
|
superoxide dismutase 1
|
affects activity
|
ISO
|
Uric Acid affects the activity of SOD1 protein
|
CTD |
PMID:10949969 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions
|
ISO
|
Uric Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in decreased expression of SOD2 protein]
|
CTD |
PMID:21767162 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
G
|
Sord
|
sorbitol dehydrogenase
|
increases expression
|
ISO
|
Uric Acid results in increased expression of SORD protein
|
CTD |
PMID:30651350 |
|
NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:129,638,302...129,686,100
|
|
G
|
Sqstm1
|
sequestosome 1
|
multiple interactions
|
ISO
|
[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of SQSTM1 protein; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased expression of SQSTM1 protein]
|
CTD |
PMID:36796188 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions increases phosphorylation
|
EXP
|
Colchicine promotes the reaction [Uric Acid results in increased phosphorylation of STAT3 protein]; simiaowan promotes the reaction [Uric Acid results in increased phosphorylation of STAT3 protein]
|
CTD |
PMID:33894285 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
G
|
Stc1
|
stanniocalcin 1
|
affects abundance
|
ISO
|
STC1 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr15:50,709,439...50,720,093
Ensembl chr15:50,709,415...50,720,082
|
|
G
|
Syk
|
spleen associated tyrosine kinase
|
multiple interactions increases phosphorylation
|
ISO
|
Apigenin inhibits the reaction [Uric Acid results in increased phosphorylation of SYK protein]; N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine inhibits the reaction [Uric Acid results in increased phosphorylation of SYK protein]
|
CTD |
PMID:29960001 |
|
NCBI chr17:12,756,493...12,830,927
Ensembl chr17:12,756,493...12,813,278
|
|
G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases secretion multiple interactions increases expression
|
ISO
|
Uric Acid results in increased secretion of TGFB1 protein [Uric Acid co-treated with TGFB1 protein] promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; [Uric Acid co-treated with TGFB1 protein] promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; ALPK1 protein promotes the reaction [Uric Acid results in increased secretion of TGFB1 protein] Uric Acid results in increased expression of TGFB1 mRNA
|
CTD |
PMID:27542954 PMID:36850003 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
G
|
Tgfbr2
|
transforming growth factor, beta receptor 2
|
multiple interactions
|
ISO
|
TGFBR2 protein affects the reaction [Uric Acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1RN protein]]; TGFBR2 protein affects the reaction [Uric Acid promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]
|
CTD |
PMID:36850003 |
|
NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469
|
|
G
|
Tlr4
|
toll-like receptor 4
|
increases expression multiple interactions
|
ISO
|
Uric Acid results in increased expression of TLR4 protein nuciferine inhibits the reaction [Uric Acid results in increased expression of TLR4 protein]
|
CTD |
PMID:25499818 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
G
|
Tmem171
|
transmembrane protein 171
|
affects abundance
|
ISO
|
TMEM171 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr 2:31,769,486...31,779,358
Ensembl chr 2:31,769,486...31,780,134
|
|
G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression
|
EXP ISO
|
Colchicine inhibits the reaction [Uric Acid results in increased expression of TNF protein]; Drugs, Chinese Herbal inhibits the reaction [Uric Acid results in increased expression of TNF mRNA]; Drugs, Chinese Herbal inhibits the reaction [Uric Acid results in increased expression of TNF protein]; evodiamine inhibits the reaction [Uric Acid results in increased expression of TNF protein]; IL17A protein affects the reaction [Uric Acid results in increased expression of TNF mRNA]; IL17A protein affects the reaction [Uric Acid results in increased expression of TNF protein] Uric Acid results in increased expression of TNF mRNA; Uric Acid results in increased expression of TNF protein salinomycin inhibits the reaction [Uric Acid results in increased expression of TNF mRNA]; salinomycin inhibits the reaction [Uric Acid results in increased expression of TNF protein]; Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF mRNA]; Uric Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]
|
CTD |
PMID:19655406 PMID:33749747 PMID:37555854 PMID:37815028 PMID:39222901 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
G
|
Tp53
|
tumor protein p53
|
increases phosphorylation
|
ISO
|
Uric Acid results in increased phosphorylation of TRP53 protein
|
CTD |
PMID:23619996 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
G
|
Trim46
|
tripartite motif-containing 46
|
affects abundance
|
ISO
|
TRIM46 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr 2:176,939,253...176,952,285
Ensembl chr 2:176,939,253...176,958,364
|
|
G
|
Ttk
|
Ttk protein kinase
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of TTK mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:93,634,319...93,672,664
|
|
G
|
Txn1
|
thioredoxin 1
|
multiple interactions
|
ISO
|
TXN protein affects the reaction [Uric Acid results in increased secretion of IL1B protein]
|
CTD |
PMID:18403674 |
|
NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307
|
|
G
|
Txnip
|
thioredoxin interacting protein
|
multiple interactions increases expression
|
EXP
|
Colchicine inhibits the reaction [Uric Acid results in increased expression of TXNIP protein]; evodiamine inhibits the reaction [Uric Acid results in increased expression of TXNIP protein]
|
CTD |
PMID:37555854 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731
|
|
G
|
Tyms
|
thymidylate synthetase
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of TYMS mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097
|
|
G
|
Ube2q2
|
ubiquitin conjugating enzyme E2 Q2
|
affects abundance
|
ISO
|
UBE2Q2 gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr 8:64,414,502...64,474,425
Ensembl chr 8:64,414,301...64,474,418
|
|
G
|
Vegfa
|
vascular endothelial growth factor A
|
affects abundance
|
ISO
|
VEGFA gene SNP affects the abundance of Uric Acid
|
CTD |
PMID:23263486 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
G
|
Xdh
|
xanthine dehydrogenase
|
multiple interactions increases abundance increases chemical synthesis
|
ISO EXP
|
Fructose promotes the reaction [XDH protein results in increased chemical synthesis of Uric Acid] XDH protein results in increased abundance of Uric Acid [2,2,5,7,8-pentamethyl-1-hydroxychroman results in decreased activity of XDH protein] which results in decreased abundance of Uric Acid; [bisphenol F results in increased activity of XDH protein] which results in increased abundance of Uric Acid [1-Naphthylisothiocyanate co-treated with Uric Acid] results in increased expression of XDH mRNA; [bisphenol A results in increased activity of XDH protein] which results in increased chemical synthesis of Uric Acid; [Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of and results in increased activity of XDH protein; caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [XDH protein results in increased chemical synthesis of Uric Acid]]; diallyl trisulfide inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased secretion of and results in increased activity of XDH protein]; Tetradecanoylphorbol Acetate promotes the reaction [XDH protein results in increased chemical synthesis of Uric Acid]
|
CTD |
PMID:17439425 PMID:19158351 PMID:21920950 PMID:22036979 PMID:31574244 PMID:33749747 PMID:36796188 PMID:37601897 More...
|
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
|
|
G
|
Xrcc1
|
X-ray repair cross complementing 1
|
multiple interactions decreases expression
|
ISO
|
NLRP3 gene mutant form inhibits the reaction [Uric Acid results in decreased expression of XRCC1 mRNA]
|
CTD |
PMID:23619996 |
|
NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613
|
|